Ironwood Pharmaceuticals

Ironwood mulls options after FDA demands further GI drug study

Ironwood has been left considering its options after the FDA demanded another trial before it will consider the biopharma’s GLP-2 analog for approval.

James Waldron Apr 14, 2025 10:51am

Ironwood makes further bid for $1B GI drug with subgroup data

Oct 28, 2024 12:33pm

starry star gazing galaxy constellations

Ironwood spies new frontier for $1B drug in exploratory trial

Mar 28, 2024 9:00am

sales decline revenue decline sales revenue stock stock market

Ironwood seeing STARS as phase 3 hit triggers 30% stock drop

Feb 29, 2024 7:52am

Ironwood pays $1B for VectivBio and its phase 3 GI drug

May 22, 2023 10:05am

Tour de biotech: Cyclerion peddles through another disease area

Oct 6, 2022 10:30am